Pembrolizumab for Thymic Carcinoma

Phase-Based Progress Estimates
Thymic CarcinomaPembrolizumab - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is studying pembrolizumab and sunitinib malate to treat thymic cancer.

Eligible Conditions
  • Thymic Carcinoma

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 24 months

Month 24
Overall survival (OS)
Progression free survival (PFS)
Up to 24 months
PD-L1 by immunohistochemistry
Response defined by a complete response (CR) or partial response (PR) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Day 30
Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment (pembrolizumab, sunitinib malate)
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Treatment (pembrolizumab, sunitinib malate)Experimental Group · 3 Interventions: Pembrolizumab, Sunitinib Malate, Laboratory Biomarker Analysis · Intervention Types: Biological, Drug, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,089 Previous Clinical Trials
41,142,240 Total Patients Enrolled
9 Trials studying Thymic Carcinoma
793 Patients Enrolled for Thymic Carcinoma
Dwight OwenLead Sponsor
4 Previous Clinical Trials
159 Total Patients Enrolled
Dwight Owen, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
OSU Harding Hospital, Ohio State University Hospital - Wexner Medical Center, Richard M. Ross Heart Hospital

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: